The therapeutic landscape for polymyalgia rheumatica (PMR) has grown and will grow further, allowing prolonged use of glucocorticoids (GCs) to be minimized, Anisha B. Dua, MD, MPH, of Feinberg School ...
The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...
For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results